ArticleInternational journal of surgery (London, England)2026
Estimating the global macroeconomic impact of colorectal cancer: evidence from Global Burden of Disease 2021 and Value of a Statistical Life Year framework.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer-related death globally. However, its macroeconomic burden remains underexplored.
methodsUsing Global Burden of Disease (GBD) 2021 data, we quantified the economic welfare loss due to CRC across 204 countries using the Value of a Statistical Life Year (VSLY) approach. The Valuation of a Statistical Life (VSL) was derived by adjusting the U.S. benchmark ($11.8 million) based on per capita gross domestic product (GDP) and income elasticity (base case: 1.0). VSLY was calculated by dividing VSL by half the national life expectancy. Country-specific Value of Lost Welfare (VLW) was estimated and expressed as a percentage of GDP (VLW/GDP). Aggregated analyses were performed by sociodemographic index (SDI) and GBD regions. Sensitivity analyses used alternative elasticity values (0.55, 1.5) and applied a 3% discount rate.
findingsIn 2021, global CRC-related VLW was estimated at $3.49 trillion (95% uncertainty interval [UI]: $3.02-$3.96 trillion), equivalent to 2.28% (95% UI: 1.97%-2.58%) of global GDP. VLW/GDP ratios were highest in high-SDI regions (2.81%) and the Central Europe, Eastern Europe, and Central Asia super-region (3.48%). At the national level, VLW ranged from <$500 million in small island states to >$0.6 trillion in China and the U.S. Discounting increased VLW estimates by 35%-67%.
conclusionsCRC imposes a substantial and inequitable economic burden, particularly in economically developed and aging societies. Incorporating VSLY into cancer burden assessments underscores the urgency of investing in prevention, early detection, and surgical capacity strengthening, especially in middle-income and resource-limited settings. GRAPHICAL ABSTRACT:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.